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Abstract
Background: Both endoscopic and surgical approaches are employed in the treatment of early gastric cancer
(EGC). The aim of this study was to establish appropriate treatment strategies for early gastric cancer.
Methods: We retrospectively examined clinicopathological data of EGC patients who had undergone surgery.
Results: A total of 327 patients (204 males and 123 females, mean age 63.2 years) were eligible for inclusion in the
study. The median follow-up period was 31 months. Of 161 mucosal (pT1a) tumors, 87 were mainly
undifferentiated and 110 had an undifferentiated component. Four patients with pT1a tumors had lymph node
metastases; all these tumors were signet-ring cell carcinomas and were macroscopic type 0-IIc with ulceration, and
only one of them had lymphatic invasion. Among patients with submucosal tumors, four of 43 patients with
pT1b1 tumors and 37 of 123 patients with pT1b2 tumors had nodal metastases. Lymph node metastases were
significantly higher in mixed undifferentiated type group than differentiated type group for both groups, pT1a-
pT1b1 (p = 0.0251) and pT1b2 (p = 0.0430) subgroups. Only four of 45 patients with nodal metastases were
diagnosed preoperatively by computed tomography (sensitivity 8.9%, specificity 96.2%). Nine patients with pT1b
tumors had recurrence after surgery, and died. The sites of initial recurrence were liver, bone, peritoneum, distant
nodes, and the surgical anastomosis.
Conclusions: The incidence of nodal metastases was approximately 5% in undifferentiated type mucosal (pT1a)
tumors, and higher in submucosal (pT1b) tumors. The sensitivity of preoperative diagnosis of nodal metastases in
EGC using computed tomography was relatively low in this study. Therefore at present surgery with adequate
lymphadenectomy should be performed as curative treatment for undifferentiated type EGC.
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Background
Gastric cancer is the fourth leading cause of cancer-
related deaths worldwide [1]. Although advanced gastric
cancer is often difficult to cure, early gastric cancer
(EGC), which is generally recognized as a tumor with
invasion confined to the mucosa or submucosa, is cur-
able because of the low incidence of lymph node metas-
tases [2]. The seventh edition of the International Union
Against Cancer TNM guidelines defines mucosal can-
cers as pT1a and submucosal cancers as pT1b [3]. The
third English edition of the Japanese Classification of
gastric carcinoma [4] submucosal tumors are further
c a t e g o r i z e sa ss u b m u c o s a lt u m o r sa sp T 1 b 1( s u b m u c o -
sal invasion < 0.5 mm) or pT1b2 (submucosal invasion
≥ 0.5 mm). Nodal metastases are rare in pT1a tumors
[5,6], but occur in 2-9.8% of pT1b1 and 12-24.3% of
pT1b2 tumors [7,8]. Surgery provides excellent cure
rates for EGC [9], especially limited gastrectomy with
[10-12] or without [13,14] lymphadenectomy. Endo-
scopic treatment is a less invasive [15] alternative which
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including endoscopic mucosal resection [17-20] and
endoscopic submucosal dissection [15,21]. However,
unsuitable use of endoscopic treatment for gastric can-
cer may result in local recurrence [22] and distant
metastases [23] in cases which might otherwise have
been curable, and should only be performed when there
is an accurate diagnosis and prognosis.
The aim of this study was to investigate the optimal
treatment strategy for EGC by evaluation of the clinico-
pathological characteristics. We focused particularly on
histological type, because histological type is the only
pathological factor which can be definitively diagnosed
preoperatively.
Methods
Patients
All cases of solitary gastric adenocarcinoma which
underwent curative surgery at the Digestive Disease
Center, Showa University Northern Yokohama Hospital
between April, 2001 and November, 2010 were retro-
spectively studied. The criteria for inclusion in the study
were: (1) adenocarcinoma of the stomach histologically
proven by endoscopic biopsy; (2) histologically solitary
tumor; (3) no prior endoscopic resection, surgery, che-
motherapy, or radiation therapy; (4) tumor invasion of
the lamina propria or submucosa. Cases with synchro-
nous or metachronous malignancy were excluded.
We examined relationships among histological type,
tumor depth, nodal metastases, and prognosis. We also
recorded the regional lymph node classification of the
preoperative diagnosis. We generally performed preo-
perative screening for nodal metastases by computed
tomography, followed by ultrasonography in cases with
suspected nodal disease. Lymph nodes ≥ 1c mi nd i a -
meter on imaging were defined as metastatic nodes. We
divided patients into four groups according to their
pathological tumor types: (1) differentiated type includ-
ing tumors mainly composed of well differentiated ade-
nocarcinoma (tub1), moderately differentiated
adenocarcinoma (tub2), or papillary adenocarcinoma
(pap), and without poorly differentiated adenocarcinoma
(por), signet-ring cell carcinoma (sig), or mucinous ade-
nocarcinoma (muc) components; (2) mixed differen-
tiated type including tumors mainly composed of tub1,
tub2, or pap, and with por, sig, or muc components; (3)
m i x e du n d i f f e r e n t i a t e dt y p eincluding tumors mainly
c o m p o s e do fp o r ,s i g ,o rm u c ,a n dw i t ht u b 1 ,t u b 2 ,o r
pap components; (4) undifferentiated type including
tumors mainly composed of por, sig, or muc, and with-
out tub1, tub2, or pap components. Disease was staged
using the seventh edition of the International Union
Against Cancer TNM guidelines [3].
All patient data were approved for use by the institu-
tional review board of Showa University Northern Yoko-
hama Hospital. Research reported in this paper was in
compliance with the Helsinki Declaration.
Statistical analysis
Fisher’s exact test was used to study relationships
between nodal metastases and clinicopathological find-
ings, and logistic regression analysis was applied to
determine correlations between histological groups and
nodal metastases. P-values less than 0.05 were consid-
ered to indicate statistical significance. Statistical analysis
was performed using JMP Statistical Discovery 9.0.2
software (SAS Institute, Cary, USA).
Results
A total of 327 patients were eligible for inclusion in the
study, including 204 males and 123 females, with a
mean age of 63.2 years (range 31-89 years). The median
follow-up period was 31 months.
The clinicopathological characteristics of patients are
shown in Table 1.
Relationships between clinicopathological characteris-
tics and nodal metastases are shown in Table 2. The
only characteristic significantly associated with nodal
metastases was lymphatic invasion in pT1b2 tumors.
We combined pT1a (m) and pT1b1 (sm1) tumors into
one group because the incidence of nodal metastases
was under 10% in both, and compared relationships
between histological types and nodal metastases in the
pT1a-pT1b1 (m-sm1) and pT1b2 (sm2) groups (Table
3). A total of 45 out of 327 patients had nodal metas-
tases, including 8 of the 204 patients in the pT1a-pT1b1
(m-sm1) group. Rates of nodal metastases were signifi-
cantly higher in the mixed undifferentiated type group
than the differentiated type group (p = 0.0251).
Of 123 patients with pT1b2 tumors (sm2 group), 37
had nodal metastases. There was a significant associa-
tion between depth of tumor invasion and nodal metas-
tases in pT1b tumors. The incidence of nodal
metastases was higher in the mixed undifferentiated
type group than in the differentiated type group (p =
0.0430).
The pathological characteristics of patients in the
pT1a-pT1b1 (m-sm1) group with nodal metastases are
shown in Table 4. All four node-positive patients with
pT1a tumors had ulceration (Figure 1). The smallest
tumor size was 10 mm in diameter. One patient had
non-perigastric nodal metastases along the common
hepatic artery.
Only 4 of 45 patients with nodal metastases were
diagnosed preoperatively (sensitivity 8.9%, specificity
96.1%).
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Page 2 of 7Nine patients had recurrence of cancer, and died. The
initial site of recurrence was liver in three patients, bone
in two, peritoneum in two, distant lymph nodes in one,
and the surgical anastomosis in one (Table 5).
Discussion
The most important factor to consider when selecting
treatment modalities for EG Ci st h ep r e s e n c eo fl y m p h
node metastases. Although nodal metastases are rare in
pT1a tumors, they have been reported to occur in 2-
9.8% [7,8] of pT1b1 tumors and 12-24.3% [7,8] of
pT1b2 tumors. Surgical treatment is generally underta-
ken for pT1b2 tumors. Detailed surveys have clarified
the pathological characteristics of EGC with or without
nodal metastases. Nodal metastases are uncommon in
differentiated type mucosal tumors [5,6,24] and in undif-
ferentiated type mucosal tumors smaller than 20 mm in
diameter without lymphatic invasion, venous invasion,
or ulceration [5,6,24].
Some limitations of this study should be considered.
As the patients in this study were excluded from endo-
scopic treatment due to the possibility of nodal metas-
tases, the incidence of nodal disease might be higher
in this group than the overall incidence in a group
which includes the patients who underwent endoscopic
treatment. In this study, the incidence of nodal metas-
tases was 2.5% in pT1a, 9.3% in pT1b1, and 30.1% in
pT1b2 tumors. Although the incidence was under 10%
in both pT1a and pT1b1 tumors, it was relatively high
in pT1b2 tumors compared with previous reports. Of
the clinicopathological variables studied, only lympha-
tic invasion in pT1b2 tumors had a significant associa-
tion with lymph node invasion. These results showed
that the clinicopathological characteristics of pT1b1
tumors were more similar to those of pT1a tumors
than those of pT1b2 tumors. We therefore combined
pT1a and pT1b1 tumors in our analysis of relation-
ships between histological types and nodal metastases.
Mixed undifferentiated type tumors had a significantly
higher incidence of nodal metastases than differen-
tiated type tumors in both the pT1a-pT1b1 and the
pT1b2 groups. Mixed histological type tumors have
previously been reported to be a risk factor for nodal
metastases [25], which is supported by our results
showing that mixed undifferentiated type tumors are a
risk factor for nodal metastases.
All four pT1a tumors and three of the pT1b1 tumors
with nodal metastases in this study were signet-ring cell
carcinomas with ulceration. The other pT1b1 tumor
with nodal metastases was a differentiated type tumor
without ulceration and without lymphatic or venous
invasion. The 37 pT1b2 tumors with nodal metastases
h a dv a r y i n gh i s t o l o g i c a lf i n d i n g s .I ts e e m e dt h a td e p t h
of tumor invasion was the most important prognostic
factor in these tumors.
We performed surgery for curative treatment of EGC
in cases which were thought to have a possibility of
nodal metastases. However, pathological diagnosis of the
surgical specimens shows that many of these cases were
overtreated by their surgery [26]. Accurate preoperative
diagnosis of the presence or absence of lymph node
metastases would simplify treatment decisions.
Table 1 Clinicopathological findings of patients with
early gastric cancer (n = 327)
Variables Number of subjects (%)
Sex
Male 204 (62.4)
Female 123 (37.6)
Gastrectomy
Distal 211 (64.5)
Proximal 34 (10.4)
Total 81 (24.8)
Partial 1 (0.3)
Surgical approarch
Laparoscopy 236 (72.2)
Hand-assist 27 (8.3)
Open laparotomy 64 (19.6)
Tumor depth *
pT1a (m) 161 (49.2)
pT1b1 (sm1) 43 (13.1)
pT1b2 (sm2) 123 (37.6)
Lymph node metastasis
†
pN0 282 (86.2)
pN1 34 (10.4)
pN2 6 (1.8)
pN3 5 (1.5)
Distant metastasis
†
M0 327 (100.0)
M1 0 (0)
Main histologic type
Differentiated 169 (51.7)
Undifferentiated 158 (48.3)
Lymphatic invasion
†
L0 246 (75.2)
L1-2 81 (24.8)
Venous invasion
†
V0 279 (85.3)
V1-3 48 (14.7)
Stage
†
IA 282 (86.2)
IB 34 (10.4)
II 6 (1.8)
IIIA 5 (1.5)
* According to the third English edition of the Japanese Classification of
Gastric Carcinoma [4].
† According to the seventh edition of the International Union Against Cancer
TNM guidelines [3].
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Page 3 of 7Table 2 Results of univariate analyses showing relationships between clinicopathological characteristics and lymph
node metastases
Variables pT1a tumor
(n = 161)
pT1b1 tumor
(n = 43)
pT1b2 tumor
(n = 123)
pN(+) p-value pN(+) p-value pN(+) p-value
Total 4/161 (2.5%) 4/43 (9.3%) 37/123 (30.1%)
Sex 0.6269 0.2802 0.8309
Male 3/88 (3.4%) 4/28 (14.3%) 26/88 (29.6%)
Female 1/73 (1.4%) 0/15 11/35 (31.4%)
Age 0.6332 0.3449 0.8432
< 65 3/91 (3.3%) 3/21 (14.3%) 16/51 (31.4%)
65 ≤ 1/70 (1.4%) 1/22 (4.6%) 21/72 (29.2%)
Main tumor site 0.1903 0.2707 0.1129
Upper 0/19 0/3 3/21 (14.3%)
Middle 4/89 (4.5%) 4/27 (14.8%) 17/59 (28.8%)
Lower 0/53 0/13 17/43 (39.5%)
Clinical macro type 0.5655 0.5579 0.4764
Depressed or excavated 3/131 (2.3%) 4/33 (12.1%) 27/96 (28.1%)
Flat or elevated 1/30 (3.3%) 0/10 10/27 (37.0%)
Pathological macro type 1.0000 1.0000 0.4764
Depressed 4/139 (2.9%) 4/37 (10.8%) 27/96 (28.1%)
Flat or elevated 0/22 0/6 10/27 (37.0%)
Ulceration 0.1287 0.3235 0.4200
No 0/72 1/23 (4.4%) 21/77 (27.3%)
Yes 4/89 (4.5%) 3/20 (15.0%) 16/46 (34.8%)
Main histologic type 0.1252 0.4672 0.8441
Differentiated 0/74 2/29 (6.9%) 19/66 (28.8%)
Undifferentiated 4/87 (4.6%) 2/14 (14.3%) 18/57 (31.6%)
Pathological tumor size 1.0000 1.0000 0.0589
≤20 mm 1/60 (1.7%) 0/7 4/28 (14.3%)
20 mm< 3/101 (2.5%) 4/36 (11.1%) 33/95 (34.7%)
Pathological tumor size 0.3083 1.0000 0.1730
≤30 mm 1/96 (1.0%) 2/21 (9.5%) 13/55 (23.6%)
30 mm< 3/65 (4.6%) 2/22 (9.1%) 24/68 (35.3%)
Lymphatic invasion
† 0.0731 0.5227 < 0.0001**
L0 3/158 (1.9%) 3/36 (8.3%) 4/52 (7.7%)
L1-2 1/3 (33.3%) 1/7 (14.3%) 33/71 (46.5%)
Venous invasion
† 1.0000 1.0000 0.4200
V0 4/160 (2.5%) 4/42 (9.5%) 21/77 (27.3%)
V1-3 0/1 0/1 16/46 (34.8%)
** p < 0.01.
† According to the seventh edition of the International Union Against Cancer TNM guidelines [3].
Table 3 Relationships among tumor depth, histological type, and lymph node metastases
Tumor depth Histologic type pN(+) Hazard ratio 95% confidence interval p-value
m-sm1 (n = 204) Differentiated 1/72 (1.4%) 1.000
Mixed differentiated 1/31 (3.2%) 2.367 0.092-61.123 0.5527
Mixed undifferentiated 3/22 (13.6%) 11.211 1.351-233.786 0.0251*
Undifferentiated 3/79 (3.8%) 2.803 0.350-57.357 0.3449
sm2 (n = 123) Differentiated 11/41 (26.8%) 1.000
Mixed differentiated 8/25 (32.0%) 1.283 0.423-3.808 0.6539
Mixed undifferentiated 8/14 (57.1%) 3.636 1.042-13.478 0.0430*
Undifferentiated 10/43 (23.3%) 0.826 0.303-2.230 0.7054
* p < 0.05
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vary. The only part of the preoperative diagnosis which
is almost definite is the histological type of the tumor.
The accuracy of the preoperative diagnosis of depth of
tumor invasion in mucosal tumors has been reported to
be 80.2% [27]. Pathological findings after ESD show
more detailed information and may indicate the need
for additional treatment [28].
Table 4 Pathological characteristics of pT1a and pT1b1 tumors with lymph node metastases
Case Tumor
depth *
Macro
type
Ulceration Tumor size,
mm
Histologic
type
L
† V
† Number of positive
node
Follow-up time,
months
Status
1 m 0-IIc Yes 10 sig, tub2 0 0 1 97 Alive
2 m 0-IIc Yes 42 sig, tub2,
muc
0 0 1 7 Alive
3 m 0-IIc Yes 60 sig 0 0 1 82 Alive
4 m 0-IIc Yes 100 sig, por,
tub1
1 0 1 25 Alive
5 sm1 0-IIc No 25 tub1 0 0 1 76 Alive
6 sm1 0-IIc Yes 25 tub2, por 2 0 4 37 Alive
7 sm1 0-IIc Yes 31 sig 1 1 11 58 Deceased (bone
metastasis)
8 sm1 0-IIc Yes 32 por, sig 1 0 1 20 Alive
* According to the third English edition of the Japanese Classification of Gastric Carcinoma [4].
† According to the seventh edition of the International Union Against Cancer TNM guidelines [3].
muc = mucinous adenocarcinoma; por = poorly differentiated adenocarcinoma; sig = signet-ring cell carcinoma; tub1 = well differentiated adenocarcinoma; tub2
= moderately differentiated adenocarcinoma.
Case 1
Case 2
Case 3
Case 4
Endoscopic 
image
Macroscopic image Signet-ring cell 
carcinoma, 
mucosal invasion
Ulceration Lymph node 
metastasis
Figure 1
Figure 1 Endoscopic, macroscopic and pathological images of mucosal tumors with lymph node metastases. Four of 161 patients with
mucosal tumors had nodal metastases. All of these patients had signet-ring cell carcinomas with ulceration. The smallest tumor was 10 mm in
diameter (Case 1). One patient had non-perigastric nodal metastases along the common hepatic artery (Case 2).
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metastases in EGC using computed tomography varies
widely by methodology [29,30]. In this study, the accu-
racy of preoperative diagnosis was relatively low, and we
did not know whether nodal metastases were present
until we performed surgery with lymphadenectomy. We
therefore selected treatment based mainly on the histo-
logical type of the tumor.
In general, we should currently perform surgery with
adequate lymphadenectomy for EGC with an undifferen-
tiated tumor type.
Conclusions
Both endoscopic and surgical approaches are employed
in the treatment of EGC. The aim of this study was to
establish appropriate strategies for the treatment of
EGC. We retrospectively examined the clinicopathologi-
cal data of EGC patients who had undergone surgery. A
total of 327 patients were eligible for the study, with a
median follow-up period of 31 months. Nodal metas-
tases were found in 4 of 161 patients with pT1a tumors;
these were all signet-ring cell carcinomas with Type 0-
IIc macroscopic appearance, and three of them did not
have lymphatic or venous invasion. Nodal metastases
were found in 4 of 43 patients with pT1b1 tumors and
37 of 123 patients with pT1b2 tumors. Lymph node
metastases were significantly higher in mixed undiffer-
entiated type group than differentiated type group for
both groups, pT1a-pT1b1 (p = 0.0251) and pT1b2 (p =
0.0430) subgroups. The sensitivity of preoperative diag-
nosis of nodal metastases was 8.9% and the specificity
was 96.1%. Nine patients with pT1b tumors had recur-
rence after surgery, with the initial sites of recurrence
being liver, bone, peritoneum, distant nodes, and the
surgical anastomosis. As the accuracy of preoperative
diagnosis of nodal metastases was relatively low, we
should at present perform surgery with adequate lym-
phadenectomy for undifferentiated type EGC.
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